Waters Corporation (WAT) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2002. Waters Corporation is the world's largest manufacturer of high performance liquid chromatography (HPLC) instruments, chromatography columns, and related services. Through subsidiaries Micromass and TA Instruments, the Company also leads in mass spectrometry and thermal analysis. The Company operates as a single reporting segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 | Six Months Ended June 30, 2002 |
|---|---|---|
| Net Sales | $217.2 million | $417.5 million |
| Gross Profit | $141.2 million (65.0% margin) | $270.1 million (64.7% margin) |
| Operating Income | $47.6 million | $91.6 million |
| Net Income | $37.9 million | $68.4 million |
| Diluted EPS | $0.28 | $0.50 |
| Cash from Operations (6mo) | $107.7 million | |
| Cash and Equivalents (End of Period) | $306.4 million | |
| Total Debt (Notes Payable) | $0.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% for the quarter and 2% for the six-month period compared to 2001. Excluding currency effects, sales grew 3% in both periods. HPLC sales grew in the high-single digits, while mass spectrometry sales declined due to patent litigation impacts in the U.S.
- Profitability: Operating income decreased 6% for the quarter and 8% for the six-month period. This decline was driven by increased operating expenses (including patent costs and headcount) despite improved gross margins and the elimination of goodwill amortization.
- Accounting Changes: The Company adopted SFAS 142, eliminating goodwill amortization. Additionally, the Company changed its accounting for patent litigation costs from capitalization to expensing as incurred, resulting in a $4.5 million cumulative charge to net income for the six-month period.
- Investment Impairments: The Company recorded $7.6 million in pre-tax charges for impairments of investments in GeneProt and Variagenics, partially offset by a $7.7 million termination fee received from GeneProt.
Guidance, Outlook, and Risks
- Patent Litigation (Applera): A jury found the Company's Quattro Ultima mass spectrometer infringed a patent, awarding $47.5 million in damages and issuing an injunction. The Company has accrued $74.2 million for this liability and intends to appeal. Approximately $55.0 million of cash will be restricted as collateral for a letter of credit in Q3 2002.
- Patent Litigation (HP): Ongoing litigation with Hewlett-Packard regarding the Alliance pump resulted in a non-material provision for estimated damages.
- Operational Strategy: The Company is integrating the sales and service groups of Micromass and Waters. Operating expense growth is expected to remain just over 10% for the remainder of 2002 before efficiency benefits are realized.
- Capital Allocation: The Board authorized a $200 million stock repurchase program. As of August 9, 2002, approximately $26.8 million had been repurchased.
- Outlook: Management expects existing cash balances and operating cash flow to be sufficient to fund operations and capital spending. No dividends are planned.
Investor Verification Checklist
- Applera Litigation Exposure: Verify the status of the appeal regarding the $47.5 million damages and the potential for additional liability beyond the $74.2 million accrual.
- Mass Spectrometry Sales: Monitor the impact of the U.S. injunction on mass spectrometry revenue and the effectiveness of the sales integration strategy.
- Working Capital Trends: Review the increase in accounts receivable days-sales-outstanding (75 days vs. 67 days) and inventory levels relative to sales expectations.
- Investment Portfolio: Assess the remaining value and risk of equity investments in unaffiliated companies following the recent impairment charges.
- Stock Repurchase Execution: Track the pace of the $200 million share buyback program initiated in July 2002.